title: Different effects of cytoprotective drugs on ethanol- and aspirin-induced gastric mucosal injury in pylorus-ligated rats.
abstract: In anesthetized rats oral administration (2 ml) of both ethanol (50% in 150 mM HCl) and aspirin (80 mM in 150 mM HCl) produced bandlike lesions in the stomach, while more generalized lesions occurred in the pylorus-ligated stomach when the irritant was given intragastrically through the fistula prepared in the rumen and the mucosal folds were removed by stomach distension. The bandlike lesions induced in the intact stomach by both irritants were significantly and dose-dependently prevented by 16,16-dimethyl PGE2 (dmPGE2: 3 and 10 micrograms/kg, subcutaneously), cysteamine (30 and 100 mg/kg, subcutaneously) or timoprazole (10 and 30 mg/kg, per os) at the doses which significantly inhibited gastric motility. In the pylorus-ligated stomach, however, neither of these agents showed any protection against the generalized lesions induced by ethanol, but such lesions caused by aspirin were significantly prevented only by dmPGE2. These agents also showed similar effects against the reduction of transmucosal PD in the pylorus-ligated stomach exposed to ethanol and aspirin. These results suggest that (1) the formation of bandlike lesions caused by ethanol and aspirin depends on the presence of mucosal folds and may be prevented by the agents that inhibit gastric motility, (2) the pathogenesis of the lesions induced by aspirin and ethanol may be different in the pylorus-ligated stomach, and (3) dmPGE2 has a unique protective ability that is not shared by usual cytoprotective agents.
authors.affiliation: Department of Applied Pharmacology, Kyoto Pharmaceutical University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Takeuchi
authors.forename: H
authors.initials: H
authors.lastname: Nishiwaki
authors.forename: H
authors.initials: H
authors.lastname: Niida
authors.forename: S
authors.initials: S
authors.lastname: Okabe
mesh_terms: D015064:16,16-Dimethylprostaglandin E2 / Q000494:pharmacology*; D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000818:Animals; D001241:Aspirin / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D003543:Cysteamine / Q000494:pharmacology*; D000431:Ethanol / Q000494:pharmacology*; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology*; D005769:Gastrointestinal Motility / Q000187:drug effects; D008026:Ligation; D009853:Omeprazole / Q000031:analogs & derivatives; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology*; D011708:Pylorus; D051381:Rats
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D011459:Prostaglandins E, Synthetic; D000431:Ethanol; D003543:Cysteamine; C038402:timoprazole; D009853:Omeprazole; D015064:16,16-Dimethylprostaglandin E2; D001241:Aspirin